Richard Scolyer

Richard Scolyer is a **Conjoint Professor** at the University of Sydney's **Faculty of Medicine and Health**, affiliated with the **Department of Pathology**. He serves as **Co-Medical Director** of the Melanoma Institute Australia and **Senior Staff Specialist (Melanoma)** at Royal Prince Alfred Hospital and NSW Health Pathology. His academic roles include contributions to the **Charles Perkins Centre** and **FMH Translational Research Collective**.

**Education**: He holds advanced qualifications including AO (Officer of the Order of Australia), BMedSci, MBBS, MD, FRCPA, FRCPath, and FAHMS.

**Research Interests**: Focus on **melanoma and skin cancer**, particularly **pathology**, **translational research**, and **immunotherapy**. Key areas include molecular mechanisms of immune evasion, tumor microenvironment analysis, and clinical trial design for advanced melanoma. His work bridges diagnostic innovation with clinical outcomes, emphasizing biomarkers and treatment response prediction.

**Awards**: Recognized with prestigious honors such as AO, FRCPA, FRCPath, and FAHMS, highlighting his leadership in medical research and administration.

**Grants/Teams**: Leads projects funded by major oncology initiatives, collaborating with institutions like the Melanoma Institute Australia. His lab focuses on melanoma progression and therapeutic resistance, with outreach to global clinical trials.

**Labs/Teams**: Central to the **Melanoma Institute Australia**, a global leader in melanoma research and treatment. Collaborates with multidisciplinary teams in surgical oncology, pathology, and immunotherapy.